Zhitong Financial APP News, Hong Kong Medical Group (02138) announced that on April 16, 2021, the company entered into a placing agreement with the placing agent, which intends to place a total of 29.636 million placing shares to Zheng Zhigang and Aspex Master Fund through the placing agent, accounting for about 2.69% of the enlarged share capital, with a placing price of HK $7.8 per share, a premium of about 1.56% over the closing price on April 16.

Assuming that the placing Agent has successfully placed all the placing shares, the net amount raised is approximately HK $231 million, which is proposed for the expansion of the Group's clinic network in Hong Kong and the Greater Bay area of China; mergers and acquisitions; and general corporate use of the Group.

It is reported that, Aspex Master Fund operates in the form of private investment funds. Aspex Management (HK) Limited is a licensed corporation incorporated in Hong Kong which can engage in Type 9 (Asset Management) regulated activities in Hong Kong under the Securities and Futures Ordinance and act as the Investment Manager of Aspex.